GOSS

Gossamer Bio, Inc. GOSS

NasdaqMid CapHealthcare

13F Pro quality score

Rank #2,893 of 2,925

Why it scores 8Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$9.24M

Quarter to Jun 30

Net income

$16.90M

Quarter to Jun 30

Free cash flow

$-39.42M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$64.24M total
TANG CAPITAL MANAGEMENT LLC
$11.47MNew
D. E. Shaw & Co., Inc.
$6.74M+33.5%
683 Capital Management, LLC
$6.45M+19.2%
DeepCurrents Investment Group LLC
$6.03M+26.1%
AQR CAPITAL MANAGEMENT LLC
$2.57M+54.3%
GSA CAPITAL PARTNERS LLP
$2.47M+360.5%
WOLVERINE ASSET MANAGEMENT LLC
$2.12M-41.4%
RENAISSANCE TECHNOLOGIES LLC
$1.91M+854.9%
Kalehua Capital Management LLC
$1.84M+49.2%
VANGUARD CAPITAL MANAGEMENT LLC
$1.55M+0.2%
ARCH Venture Management, LLC
$1.33M0.0%
BARCLAYS PLC
$1.29M+155.5%
Octagon Capital Advisors LP
$1.28M0.0%
BlackRock, Inc.
$1.26M-54.4%
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP
$1.25MNew
TWO SIGMA INVESTMENTS, LP
$1.22M+55.5%
Samsara BioCapital, LLC
$1.19M0.0%
Qube Research & Technologies Ltd
$1.16M+43.7%
Corient Private Wealth LLC
$927.1K+41.3%
Siren, L.L.C.
$857.4K0.0%
Hillhouse Capital Advisors, Ltd.
$818.7K0.0%
Murchinson Ltd.
$642.8KNew
UBS Group AG
$510.5K-81.0%
Squarepoint Ops LLC
$420.8K-24.8%
GEODE CAPITAL MANAGEMENT, LLC
$408.7K-49.8%
See all 173 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/GOSS

Earnings Per Share

13fpro.ai/company/GOSS

Loading ratio trend…

GOSS key financials by period

Reported revenue, net income and operating margin by fiscal year, from Gossamer Bio, Inc.'s annual filings on SEC EDGAR.

Gossamer Bio, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$48.5M$-170.4M—
FY 2024$114.7M$-56.5M-52.2%
Source: GOSS filings on SEC EDGAR →

Companies similar to GOSS

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

GOSS insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Gossamer Bio, Inc. (GOSS): stock profile, AI score and financials

Gossamer Bio, Inc. (GOSS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores GOSS at 8.3/100 on a composite quality score built from its SEC filings, placing it at rank #2,893 of 2,925 stocks — the bottom half of the AI-ranked universe. Areas of concern include institutional flow (0.3) and balance sheet strength (1.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 8.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Gossamer Bio, Inc. reports quarterly revenue of $9.2M, net income of $16.9M, free cash flow of $-39.4M. GOSS trades on the Nasdaq exchange and files with the SEC under CIK 1728117. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GOSS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Gossamer Bio, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1728117 →